| Trial ID # | Retrospective Study: Adjuvant Hormone Therapy in LGSC |
| Phase | Two sites |
| Drug Class | Hormonal Therapy: Aromatase |
| Drug Name | Letrozole |
| Alternate Drug Names | Femara |
| Drugs in Trial | Letrozole, Tamoxifen, Anastrozole |
| Eligible Participant | Stage II-IV low grade serous ovarian cancer |
| Patients Enrolled | 27; 85% optimally debulked, 96% HR+, 32% PR+ |
| Therapy Setting | First-line |
| Study Design | Open-Label, Non-randomized |
| Endpoints | PFS, OS, evaluated per RECIST |
| Efficacy | Surgery+adjuvant hormone therapy: PFS: Not Reached (41 months follow up) 2 year PFS and OS: 82.8% and 96.3% |
| Conclusion | Promising PFS and OS in Low Grade Serous Cancer patients treated with hormone therapy following cytoreductive surgery |
| Reference | Fader AN et al. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecol Oncol (2017) 147: 85-91 |